王金勇，研究員（二級），中國科學院大學博士生導師，獲中國科學院大學優秀教師（領雁銀獎-振翅獎），必威精装版app西汉姆联 幹細胞與再生醫學創新研究院、器官再生與智造全國重點實驗室血液與免疫細胞再生研究組組長，國家科技部重點研發計劃項目首席科學家、獲國家自然科學基金委醫學部傑出青年科學基金資助。研究組長期從事血液與免疫細胞再生的新理論測試、新技術開發、以及新型細胞的臨床轉化研究。課題組的研究發現包括：Runx1+Hoxa9二因子驅動幹細胞向T細胞譜係命運決定；Lhx2+Runx1+Hoxa9三因子驅動幹細胞向B細胞譜係命運決定；Hoxa10+Runx1+Hoxa9三因子驅動幹細胞向多譜係造血命運決定；以及Hoxb5因子驅動B細胞體內轉分化為T細胞等。在理論上，上述研究支持了血液與免疫譜係命運可以通過轉錄因子操縱實現關口前移到內皮細胞階段的理論。轉化方麵，開發出了誘導人的多能幹細胞高效分化為NK細胞的技術體係，較傳統方法提高效率100倍，開發的NK細胞產品（JK500細胞注射液）推進到臨床IIT（ClinicalTrials.gov 臨床試驗注冊號: NCT05519384）。

個人經曆

2021年6月至今：必威精装版app西汉姆联 ，研究員

2012年3月-2021年5月：中國科學院廣州生物醫藥與健康研究院，研究員

2007年9月-2012年2月：美國威斯康星醫學院、威斯康星大學麥迪遜醫學與公共衛生學院，博士後

2006年8月-2007年8月：中國農業科學院上海獸醫研究所， 博士後

2001年-2006年：浙江大學， 博士

1997年-2001年：萊陽農學院，學士

血液與免疫細胞再生

1. 幹細胞與造血幹祖細胞再生

基於多能幹細胞(ESC/iPSC)譜係分化原理，結合基因編輯，誘導獲得可移植的造血幹祖細胞種子，探索代替傳統骨髓移植細胞來源，實現治療腫瘤、遺傳病、感染、器官退行衰老、病理炎症等適應症的目的。

2. 幹細胞與免疫細胞再生（T, B, NK等免疫細胞）

基於多能幹細胞（ESC/iPSC)譜係分化原理，結合基因編輯，獲得可移植的淋巴細胞祖細胞，模擬淋巴細胞發育微環境，進一步製備成熟的B, T, NK細胞。結合細胞療法原理，探索治療腫瘤和相關免疫疾病。

1. Hu, F., J. Li, Y. Wang, Y. Lin, J. Zhang, J. Xu, X. Zheng, Q. Weng, X. Liu, Y. Geng, H. Wu, L. Liu, H. Peng, B. Wu, D. Huang, C. Xia, T. Wang, X. Du, H. Zeng, F. Dong, Y. Zhang, X. Zhu, M. Zhang and J. Wang (2025). “Large-scale generation of iNK and CAR-iNK cells from CD34+ hematopoietic stem and progenitor cells for adoptive immunotherapy.” Nature Biomedical Engineering.
2. Wang, Y., X. Zheng, Z. Wang, Z. Xiao, Y. Lin, F. Zhang, Y. Liu, P. Liu, Q. Weng, L. Zhang, C. Xia, D. Huang, L. Liu, Y. Zhu, Q. Zhang, H. Qi, Y. Chen, Y. Shen, C. Zhang, J. Xu, Y. Zhao, J. Wu, T. Wang, M. Zhang, M. Li, W. Qian, A. Liang, X. Du, W. Yang, T. Hu, Q. Chen, X. Zhu, F. Hu and J. Wang (2025). "CD33(KO)-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia." J Immunother Cancer 13(9).
3. Lin, Y., Z. Xiao, F. Hu, X. Zheng, C. Zhang, Y. Wang, Y. Liu, D. Huang, Z. Wang, C. Xia, Q. Weng, L. Zhang, Y. Zhao, H. Qi, Y. Shen, Y. Chen, F. Zhang, J. Wu, P. Liu, J. Xu, L. Liu, Y. Zhu, J. Zhang, W. Qian, A. Liang, X. Zhu, T. Wang, M. Zhang and J. Wang (2025). "Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies." J Hematol Oncol 18(1): 57.
4. Zhang, Q., C. Xia, Q. Weng, L. Zhang, Y. Wang, Y. Liu, X. Zheng, Y. Lin, Y. Chen, Y. Shen, H. Qi, L. Liu, Y. Zhu, M. Zhang, D. Huang, F. Hu, M. Zhang, H. Zeng, J. Wang and T. Wang (2024). "Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals." Front Immunol 15: 1504459.
5. Liu, Y., M. Zhang, X. Shen, C. Xia, F. Hu, D. Huang, Q. Weng, Q. Zhang, L. Liu, Y. Zhu, L. Wang, J. Hao, M. Zhang, T. Wang and J. Wang (2024). "Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals." Cell Prolif: e13727.
6. Wang, Y., J. Li, Z. Wang, Y. Liu, T. Wang, M. Zhang, C. Xia, F. Zhang, D. Huang, L. Zhang, Y. Zhao, L. Liu, Y. Zhu, H. Qi, X. Zhu, W. Qian, F. Hu and J. Wang (2024). "Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti-tumour activity." Cell Prolif: e13683.
7. Peng, H., Y. Lin, F. Hu, C. Lv, B. Wu, Q. Weng, L. Liu, C. Xia, X. Liu, Y. Zhao, Q. Zhang, Y. Geng, M. Zhang and J. Wang (2023). "Prolonged generation of multi-lineage blood cells in wild-type animals from pluripotent stem cells." Stem Cell Reports 18(3): 720-735.
8. Wu, B., Q. Zhang, P. Hong, L. Liu, H. Peng, C. Xia, T. Wang, Y. Wang, Q. Weng, X. Liu, Y. Geng, J. Wang and H. Wu (2023). "Antigen-specific TCR-T cells from Rag2 gene-deleted pluripotent stem cells impede solid tumour growth in a mouse model." Cell Prolif: e13389.
9. Xiong, J., Y. Zhao, Y. Lin, L. Chen, Q. Weng, C. Shi, X. Liu, Y. Geng, L. Liu, J. Wang and M. Zhang (2022). "Identification and characterization of innate lymphoid cells generated from pluripotent stem cells." Cell Rep 41(5): 111569.
10. Huang, D., J. Li, F. Hu, C. Xia, Q. Weng, T. Wang, H. Peng, B. Wu, H. Wu, J. Xiong, Y. Lin, Y. Wang, Q. Zhang, X. Liu, L. Liu, X. Zheng, Y. Geng, X. Du, X. Zhu, L. Wang, J. Hao and J. Wang (2022). "Lateral plate mesoderm cell-based organoid system for NK cell regeneration from human pluripotent stem cells." Cell Discov 8(1): 121.
11. Huang, D., Q. Zhao, M. Zhang, Q. Weng, Q. Zhang, K. Wang, F. Dong, H. Cheng, F. Hu and J. Wang (2022). "Hoxb5 reprogrammes murine multipotent blood progenitors into haematopoietic stem cell-like cells." Cell Prolif 55(6): e13235.
12. Yu, B., B. Wu, P. Hong, H. Peng, M. Zhang, Q. Zhang, L. Liu, X. Liu, Y. Geng, J. Wang and Y. Lan (2022). "Co-Expression of Runx1, Hoxa9, Hlf, and Hoxa7 Confers Multi-Lineage Potential on Hematopoietic Progenitors Derived From Pluripotent Stem Cells." Front Cell Dev Biol 10: 859769.
13. Zhang, Q., B. Wu, Q. Weng, F. Hu, Y. Lin, C. Xia, H. Peng, Y. Wang, X. Liu, L. Liu, J. Xiong, Y. Geng, Y. Zhao, M. Zhang, J. Du and J. Wang (2022). "Regeneration of immunocompetent B lymphopoiesis from pluripotent stem cells guided by transcription factors." Cell Mol Immunol 19(4): 492-503.
14. Wang, T., C. Xia, Q. Weng, K. Wang, Y. Dong, S. Hao, F. Dong, X. Liu, L. Liu, Y. Geng, Y. Guan, J. Du, T. Cheng, H. Cheng and J. Wang (2022). "Loss of Nupr1 promotes engraftment by tuning the quiescence threshold of hematopoietic stem cell repository via regulating p53-checkpoint pathway." Haematologica 107(1): 154-166.
15. Zhou, P., C. Xia, T. Wang, Y. Dong, Q. Weng, X. Liu, Y. Geng, J. Wang and J. Du (2021). "Senescent bone marrow microenvironment promotes Nras-mutant leukemia." J Mol Cell Biol 13(1): 72-74.
16. Lv, C., S. Chen, F. Hu, D. Huang, T. Wang, J. Du, J. Wang and H. Wu (2021). "Pluripotent stem cell-derived CD19-CAR iT cells effectively eradicate B-cell lymphoma in vivo." Cell Mol Immunol 18(3): 773-775.
17. Xia, C., T. Wang, H. Cheng, Y. Dong, Q. Weng, G. Sun, P. Zhou, K. Wang, X. Liu, Y. Geng, S. Ma, S. Hao, L. Xu, Y. Guan, J. Du, X. Du, Y. Li, X. Zhu, Y. Shi, S. Xu, D. Wang, T. Cheng and J. Wang (2020). "Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment." Leukemia 34(9): 2375-2383.
18. Guo, R., F. Hu, Q. Weng, C. Lv, H. Wu, L. Liu, Z. Li, Y. Zeng, Z. Bai, M. Zhang, Y. Liu, X. Liu, C. Xia, T. Wang, P. Zhou, K. Wang, Y. Dong, Y. Luo, X. Zhang, Y. Guan, Y. Geng, J. Du, Y. Li, Y. Lan, J. Chen, B. Liu and J. Wang (2020). "Guiding T lymphopoiesis from pluripotent stem cells by defined transcription factors." Cell Res 30(1): 21-33.
19. Guo, R., H. Wu, J. Du and J. Wang (2020). "T cell regeneration: an update on progress and challenges." Blood Sci 2(1): 22-26.
20. Hu, F., D. Huang, Y. Luo, P. Zhou, C. Lv, K. Wang, Q. Weng, X. Liu, Y. Guan, Y. Geng, J. Du, J. Chen, J. Wang and H. Wu (2020). "Hematopoietic lineage-converted T cells carrying tumor-associated antigen-recognizing TCRs effectively kill tumor cells." J Immunother Cancer 8(2).
21. Wang, T., C. Lv, F. Hu, L. Liu and J. Wang (2020). "Two-step protocol for regeneration of immunocompetent T cells from mouse pluripotent stem cells." Blood Sci 2(3): 79-88.
22. Dong, Y., K. Wang, Q. Weng, T. Wang, P. Zhou, X. Liu, Y. Geng, L. Liu, H. Wu, J. Wang and J. Du (2020). "NUP98-HOXA10hd fusion protein sustains multi-lineage haematopoiesis of lineage-committed progenitors in transplant setting." Cell Prolif 53(9): e12885.
23. Zhang, M., Y. Dong, F. Hu, D. Yang, Q. Zhao, C. Lv, Y. Wang, C. Xia, Q. Weng, X. Liu, C. Li, P. Zhou, T. Wang, Y. Guan, R. Guo, L. Liu, Y. Geng, H. Wu, J. Du, Z. Hu, S. Xu, J. Chen, A. He, B. Liu, D. Wang, Y. G. Yang and J. Wang (2018). "Transcription factor Hoxb5 reprograms B cells into functional T lymphocytes." Nat Immunol 19(3): 279-290.
24. Weng, Q., F. Hu, M. Zhang, Y. Dong, C. Lv, Y. Wang, X. Liu and J. Wang (2018). "A protocol for generating induced T cells by reprogramming B cells in vivo." Cell Regen 7(1): 7-15.
25. Wang, T., C. Xia, Y. Dong, X. Chen, J. Wang and J. Du (2018). "Trim27 confers myeloid hematopoiesis competitiveness by up-regulating myeloid master genes." J Leukoc Biol 104(4): 799-809.
26. Li, X., C. Xia, T. Wang, L. Liu, Q. Zhao, D. Yang, F. Hu, M. Zhang, K. Huang, Y. Geng, Y. Zheng, Y. Guan, H. Wu, X. Chen, G. Pan, J. Chen, J. Du and J. Wang (2017). "Pyrimidoindole derivative UM171 enhances derivation of hematopoietic progenitor cells from human pluripotent stem cells." Stem Cell Res 21: 32-39.
27. Wang, T., C. Li, C. Xia, Y. Dong, D. Yang, Y. Geng, J. Cai, J. Zhang, X. Zhang and J. Wang (2015). "Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo." Am J Transl Res 7(10): 1963-1973.
28. Chen, X., Q. Zhao, C. Li, Y. Geng, K. Huang, J. Zhang, X. Wang, J. Yang, T. Wang, C. Xia, X. Liu, M. Meng, D. Yang, Y. Zheng, J. Du, X. Zhang, J. Chen, G. Pan and J. Wang (2015). "OP9-Lhx2 stromal cells facilitate derivation of hematopoietic progenitors both in vitro and in vivo." Stem Cell Res 15(2): 395-402.
29. Yang, D., X. Zhang, Y. Dong, X. Liu, T. Wang, X. Wang, Y. Geng, S. Fang, Y. Zheng, X. Chen, J. Chen, G. Pan and J. Wang (2015). "Enforced expression of Hoxa5 in haematopoietic stem cells leads to aberrant erythropoiesis in vivo." Cell Cycle 14(4): 612-620.
30. Wang, J., G. Kong, Y. Liu, J. Du, Y. I. Chang, S. R. Tey, X. Zhang, E. A. Ranheim, M. K. Saba-El-Leil, S. Meloche, A. Damnernsawad, J. Zhang and J. Zhang (2013). "Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions." Blood 121(26): 5203-5207.
31. Wang, J., Y. Liu, Z. Li, Z. Wang, L. X. Tan, M. J. Ryu, B. Meline, J. Du, K. H. Young, E. Ranheim, Q. Chang and J. Zhang (2011). "Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner." Blood 118(2): 368-379.
32. Wang, J., Y. Liu, Z. Li, J. Du, M. J. Ryu, P. R. Taylor, M. D. Fleming, K. H. Young, H. Pitot and J. Zhang (2010). "Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia." Blood 116(26): 5991-6002.